已收盤 11-20 16:00:00 美东时间
+0.040
+3.92%
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the same period last year.
11-16 21:35
ALX Oncology reported Q3 2026 financial results with $147.2M in cash and a net loss of $21.8M. The company highlighted progress in its ALX2004 Phase 1 study, expecting safety and efficacy data in December 2026, and ASPEN-09-Breast Phase 2 trial, with topline data anticipated in H2 2027. Evorpacept showed encouraging results in the ASPEN-06 trial, reinforcing its potential in treating HER2-positive cancers. ALX Oncology remains focused on advancin...
11-16 13:00
ALX Oncology Holdings Inc. announced that its leadership will participate in fireside chats at three upcoming investor conferences: the UBS London Healthcare Conference on November 17, 2026; the Jefferies London Healthcare Conference on November 18, 2026; and the Piper Sandler Annual Healthcare Conference on December 1, 2026. Webcasts of the chats will be available on ALX Oncology’s website, with replays archived for 90 days. ALX Oncology is a cl...
11-10 13:00
In a report released on October 16, Derek Archila from Wells Fargo maintained a...
10-18 20:35
ALX Oncology Holdings ( ($ALXO) ) has shared an announcement. On October 14, 20...
10-16 05:14
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease Subgroup analyses support CD47 expression as a predictive biomark...
09-28 20:03
ALX Oncology's ASPEN-06 Phase 2 trial demonstrated that evorpacept combined with trastuzumab, ramucirumab, and paclitaxel achieved a 40.3% ORR in HER2-positive advanced gastric or GEJ cancer, compared to 26.6% for control. Among patients with high CD47 expression, ORR increased to 63.6% versus 23.1%. These findings validate CD47 as a predictive biomarker and support ALX Oncology's biomarker-driven strategy. The company remains focused on its Phas...
09-28 12:00
ALX Oncology Holdings Inc. announced that its leadership will participate in fireside chats at three upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, in Boston; the Cantor Global Healthcare Conference on September 10, 2026, in New York; and the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, also in New York. Webcasts of the fireside chats will be available on A...
09-02 12:00
ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 75 percent increase over losses of $(0.44) per share from the same period last year.
08-06 20:39
ALX Oncology press release (ALXO): Q2 GAAP EPS of -$0.13. Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of June 30, 2026, were $153.4 million. The Company believes ...
08-06 20:14